在COVID-19患者中的IL-24:与疾病进展的相关性
Richard Vollenberg1, Katharina Schütte-Nütgen2, Markus Strauss3,4
1Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Muenster, 48149 Muenster, Germany.
International journal of molecular sciences
|September 13, 2025
概括
在轻度的COVID-19病例中,干白素-24 (IL-24) 血清水平较高,这表明它具有保护作用. 在严重的COVID-19中,较低的IL-24水平表明免疫调节受损,突出显示IL-24是潜在的生物标志物.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 生物化学 生物化学
背景情况:
- 介乐-24 (IL-24) 是一种参与免疫反应和亡的细胞因子.
- 在包括COVID-19在内的病毒感染中IL-24的作用需要进一步调查.
- 了解IL-24与COVID-19严重程度的关联对于潜在的治疗策略至关重要.
研究的目的:
- 研究血清IL-24水平与COVID-19的严重程度之间的关系.
- 为了确定IL-24是否可以作为COVID-19疾病进展的生物标志物.
主要方法:
- 一项前性,双中心的横截面研究,涉及41名COVID-19患者.
- 在急性或康复阶段使用ELISA试验测量IL-24血清水平.
- 分析炎症标志物和/肝功能参数,与IL-24水平相关.
主要成果:
- 与患有严重,严重或中度疾病患者相比,在轻度COVID-19患者中发现IL-24血清水平升高.
- 较高的IL-24水平与缺乏氧化障碍相关.
- 在IL-24水平和炎症标志物和肝/功能受损之间观察到负相关性.
结论:
- 升高的IL-24血清水平与较温和的COVID-19疾病过程有关.
- 通过调节免疫反应和促进亡,IL-24可能在COVID-19中发挥保护作用.
- 在严重病例中IL-24水平降低表明免疫调节受损,表明作为生物标志物和治疗点的潜力.
相关概念视频
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:29Pneumonia II: Pathophysiology
The pathophysiology of pneumonia involves the following steps:
01:30Pneumonia III: Complications and Assessment
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
01:19Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...